<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OCUFEN- flurbiprofen sodium solution/ drops </strong><br>Allergan, Inc.<br></p></div>
<h1>OCUFEN<span class="Sup">®</span><br>(flurbiprofen sodium ophthalmic solution, USP) 0.03%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">sterile
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First"><span class="Bold">OCUFEN<span class="Sup">®</span></span> (flurbiprofen sodium ophthalmic solution, USP) 0.03% is a sterile topical nonsteroidal anti-inflammatory product for ophthalmic use.
</p>
<p><span class="Bold">Chemical Name:</span></p>
<p>Sodium (±)-2-(2-fluoro-4-biphenylyl) propionate dihydrate.
</p>
<p><span class="Bold">Structural Formula:</span></p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a4d5684-b20a-4fde-a808-404c7b9d25b3&amp;name=chemicalstructure.jpg"><p class="MultiMediaCaption">C<span class="Sub">15</span>H<span class="Sub">12</span>FNaO<span class="Sub">2</span>•2H<span class="Sub">2</span>O    Mol. Wt. 302.27</p>
</div>
<p><span class="Bold">Contains: Active:</span> flurbiprofen sodium 0.03% (0.3 mg/mL). <span class="Bold">Preservative:</span> thimerosal 0.005%. <span class="Bold">Inactives:</span> citric acid; edetate disodium; polyvinyl alcohol 1.4%; potassium chloride; purified water; sodium chloride; and sodium citrate. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH. The pH of <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution is 6.0 to 7.0. It has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 260 - 330 mOsm/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins.
</p>
<p>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed on animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.
</p>
<p>Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution has been shown to inhibit the <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> induced during the course of <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. Results from clinical studies indicate that flurbiprofen sodium has no significant effect upon intraocular pressure.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution is indicated for the inhibition of intraoperative <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution is contraindicated in individuals who are hypersensitive to any components of the medication.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.
</p>
<p>There is the potential for cross-sensitivity to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s10"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s11"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
</p>
<p>It is recommended that <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution be used with caution in surgical patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s99"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.
</p>
<p>To avoid the potential for cross-contamination, the patient should be advised to use one bottle for each eye with  bilateral ocular surgery. The use of the same bottle of eye drops for both eyes is not recommended with ocular surgery.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s12"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Interaction of <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution with other topical ophthalmic medications has not been fully investigated.
</p>
<p>Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been  reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in mice and/or rats have shown no evidence of carcinogenicity with flurbiprofen. Long-term mutagenicity studies in animals have not been performed.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s14"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.5.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of  0.4 mg/kg (approximately 300 times the human daily topical dose) and above.
</p>
<p>There are no adequate and well-controlled studies in pregnant women.  <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s16"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from flurbiprofen sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s17"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s18"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Transient burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation and other minor symptoms of ocular irritation have been reported with the use of <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution.  Other adverse reactions reported with the use of <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution include: <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphema</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, and <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>.
</p>
<p>Increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span> of ocular tissues in conjunction with ocular surgery has also been reported (see <a href="#s9">Warnings</a>).
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s20"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s21"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">A total of four (4) drops of <span class="Bold">OCUFEN<span class="Sup">®</span></span> ophthalmic solution should be administered by instilling one (1) drop approximately every 1/2 hour beginning 2 hours before surgery.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s22"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First"><span class="Bold">OCUFEN<span class="Sup">®</span></span> (flurbiprofen sodium ophthalmic solution, USP) is available for topical ophthalmic administration as a 0.03% sterile solution, and is supplied in a white opaque low density polyethylene bottle with a controlled dropper tip and a gray high impact polystyrene cap in the following size:
</p>
<dl class="Disc">
<dt> 
</dt>
<dd>2.5 mL in 5 mL bottle - NDC 11980-801-03
</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="e22"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15°-25°C (59°-77°F).<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Revised: 07/2012</span><br>© 2012 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>® marks owned by Allergan, Inc.
</p>
<p><a name="f04"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a4d5684-b20a-4fde-a808-404c7b9d25b3&amp;name=allerganlogo.jpg"></p>
<p>71587US13
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j1"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">ALLERGAN</span></p>
<p>NDC 11980-801-03
</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">OCUFEN®</span></p>
<p>(flurbiprofen
</p>
<p>sodium ophthalmic
</p>
<p>solution, USP)
</p>
<p>0.03%
</p>
<p>sterile
</p>
<p><span class="Bold">2.5 mL</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a4d5684-b20a-4fde-a808-404c7b9d25b3&amp;name=carton.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j2"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">ALLERGAN</span></p>
<p><span class="Bold">NDC</span> 11980-801-03 <span class="Bold">Rx Only</span></p>
<p><span class="Bold">OCUFEN®</span></p>
<p>(flurbiprofen sodium
</p>
<p>ophthalmic solution, USP) 0.03%
</p>
<p><span class="Bold">2.5 mL</span> sterile
</p>
<div class="Figure">
<a name="f03"></a><img alt="Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a4d5684-b20a-4fde-a808-404c7b9d25b3&amp;name=label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OCUFEN 		
					</strong><br><span class="contentTableReg">flurbiprofen sodium solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:11980-801</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>flurbiprofen sodium</strong> (flurbiprofen) </td>
<td class="formItem">flurbiprofen sodium</td>
<td class="formItem">0.3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>thimerosal</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:11980-801-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019404</td>
<td class="formItem">01/01/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(11980-801)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e41e9af7-b6ef-4c26-bbe9-5ea9e31f45c8</div>
<div>Set id: 5a4d5684-b20a-4fde-a808-404c7b9d25b3</div>
<div>Version: 6</div>
<div>Effective Time: 20120103</div>
</div>
</div> <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
